ライフサイエンスコーパス: dimethoxy

1 : 3,4-methylenedioxy > 2,3-dimethoxy >> 3, 4-dimethoxy.

2 oped using the triazine-based reagent 4-(4,6-dimethoxy (1,3,5)triazin-2-yl)-4-methylmorpholinium chlo

3 oxidants such as tert-butylhydroquinone, 2,3-dimethoxy-1, 4-naphthoquinone, and menadione.

4 4,7-Dimethoxy-1,10-phenanthroline (L1c) was found to be an e

5 Ro 4-1284 (2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo[al pha]chinolizin h

6 and (S)-11) and the 2-l-menthoxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinaldonitriles ((S)-19/

7 eaction with the condensation reagent 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chlor

8 ing noscapine analog, (R)-9-bromo-5-((S)-4,5-dimethoxy-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-met

9 ive quinone segment found in ubiquinone, 2,3-dimethoxy-1,4-benzoquinone, coupled to a boron-dipyrrome

10 associated with high levels of 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside (HDMBOA-Glc) an

11 enses, and the accumulation of 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside in leaves.

12 the benzoxazinoid phytoalexin 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside.

13 ralexins and the benzoxazinoid 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one-glucose (HDMBOA-glucose)

14 s was induced in virus-infected cells by 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) treatment.

15 sence of oxidative stress as supplied by 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), which generates a l

16 ndrial reactive oxygen species generator 2,3-dimethoxy-1,4-naphthoquinone elicits necrosis characteri

17 with 0.5 microM staurosporine or 0.3 mM 2,3-dimethoxy-1,4-naphthoquinone induced the characteristic

18 extracts against hydrogen peroxide- and 2,3-dimethoxy-1,4-naphthoquinone-induced DNA damage, and lev

19 verproduction of ROS by the redox cycler 5,8-dimethoxy-1,4-naphthoquinone.

20 posure was followed by acute exposure to 2,3-dimethoxy-1,4-napthoquinone (DMNQ), an agent that increa

21 -selective potentiator [(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoqui

22 ctural determinants for (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoqui

23 rahydroisoquinoline CIQ (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoqui

24 own naphthalene derivatives, 1,2-dihydro-2,2-dimethoxy-1-(3-alkenylidene)naphtho[2,1-b]furans.

25 imethoxy-4-(2-propen-1-yl)phenoxy]ethyl]-3,4-dimethoxy-1-acetate, (3) odoratisol A, phenol, 4-[(2S,3S

26 E2020 (R,S)-1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl)piperidine hydrochlorid

27 starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and

28 The 1,2-dimethoxy-1-methyl-2-(2,2-diphenylcyclopropyl)ethyl radi

29 aphragm muscles were treated with either 2,3-dimethoxy-1-naphthoquinone (DMNQ; 1, 10, 100 microm; a m

30 indolyl (compound 38) or a 6'-hydroxyl-2',4'-dimethoxy-1-phenyl (compound 27) moiety (A-ring) and two

31 2,2-Dimethoxy-1-phenylpropane (18) is observed as a minor pr

32 inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxo ethanone

33 6, 3) and 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane -1,2-dion

34 key oncogenic kinase, was masked by a 2-4,5-dimethoxy 2-nitrobenzyl (DMNB) moiety.

35 hybrid ligand (2-(dicyclohexylphosphino)-3,6-dimethoxy-2',6'-diisopropoxybiphenyl) demonstrated that

36 The optimal structure, 2-chloro-4',6'-dimethoxy-2'-hydroxychalcone, induced both a potent NF-E

37 Two reference standards, 6,6'-dimethoxy-2,2',3,3',4,4',5,5'-octabromodiphenyl ether (6

38 (8), 4,4'-dimethyl-2,2'-bipyridine (9), 4,4'-dimethoxy-2,2'-bipyridine (10), dimethyl 2,2'-bipyridine

39 Films prepared by crosslinking [P20-Os(4,4'-dimethoxy-2,2'-bipyridine)2(4-aminomethylpyridine)Cl].PF

40 yme catalyst, osmium redox polymers [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly(vinylimidazole))10Cl](+

41 dazole))10Cl](+) [Os(dmbpy)PVI] and [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly-(vinylimidazole))10Cl](

42 onsist of glucose dehydrogenase and [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly-vinylimidazole)10Cl](+)

43 bility to inhibit TRAP activity and [Au(4,4'-dimethoxy-2,2'-bipyridine)Cl2][PF6] (AubipyOMe) was foun

44 MeO)bpy)Cu(I)(OTf) and ABNO ((MeO)bpy = 4,4'-dimethoxy-2,2'-bipyridine; ABNO = 9-azabicyclo[3.3.1]non

45 Thus, 4-(2-aminoethyl)-6,7-dimethoxy-2,3-dihydrobenzofuran hydrochloride (8) and 1-

46 A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylami

47 benzene bis(formic acid) complex 10, and 1,4-dimethoxy-2,5-bis(2-pyridinium)benzene bis(tetrafluorobo

48 ructural and spectroscopic properties of 1,4-dimethoxy-2,5-bis(2-pyridyl)benzene (9) and the related

49 X-ray crystallographic analysis of 9, 1,4-dimethoxy-2,5-bis(2-pyridyl)benzene bis(formic acid) com

50 ines 3, or 2-phenoxyethylamine (11) with 2,5-dimethoxy-2,5-dihydrofuran (5) or 2-formylbenzoic acid (

51 ly prepared in total 70-84% yields from 2, 5-dimethoxy-2,5-dihydrofuran (7), primary amines 8, and be

52 obenzyltrichloroacetate and alpha-phenyl-4,5-dimethoxy-2,6-dinitrobenzyltrichloroacetate showed appro

53 mine D3R-prefering antagonist U-99194A [5, 6-dimethoxy-2-(di-n-propylamino)indan], suggesting that ac

54 5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was

55 ogues of penclomedine (PEN, 3,5-dichloro-4,6-dimethoxy-2-(trichloromethyl)pyridine) and its metabolit

56 Penclomedine [3,5-dichloro-4,6-dimethoxy-2-(trichloromethyl)pyridine], an antitumor age

57 all molecule GnRH receptor antagonist N-{4,6-dimethoxy-2-[(3-morpholin-4-ylpropyl)amino]pyrimidin-5-y

58 nt nAChR ligand to come from the series, 6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (3c) (

59 xidant MitoQ (mitoquinone mesylate: [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cycloheexadienl-yl) dec

60 d antioxidant mitoquinone mesylate {[10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decy

61 late to an amide by synthesizing (E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)meth

62 y a Lewis acid-catalyzed condensation of 1,3-dimethoxy-2-methylbenzene with paraformaldehyde in o-dic

63 el-Crafts acylation, chromenylation with 4,4-dimethoxy-2-methylbutan-2-ol, cyclization, and Luche red

64 ed with those of a non-cycling analogue (2,4-dimethoxy-2-methylnaphthalene (DMN)) using real-time con

65 The molecule 1-hydroxy-5,7-dimethoxy-2-naphthalene-carboxaldehyde (HDNC, marmelin)

66 The 4-nitro (4) and 4,5-dimethoxy-2-nitro (6) analogues also appear to be reduce

67 The ability of 4-nitro (4) and 4,5-dimethoxy-2-nitro (6) analogues to reach and kill hypoxi

68 Of these, the 4,5-dimethoxy-2-nitro analogue 6 (50 microM, 1-h exposure) c

69 -1,3,6-trisulfonic acid (DMNB-HPTS) and (4,5-dimethoxy-2-nitrobenzyl) fluorescein dextran (10,000 MW)

70 usion of the caged fluorescent dyes: 8-((4,5-dimethoxy-2-nitrobenzyl)oxy)pyrene-1,3,6-trisulfonic aci

71 from the respective "caged" precursors, 4,5-dimethoxy-2-nitrobenzyl-capsaicin and P(3)-[1-(4,5-dimet

72 alpha-Phenyl-4,5-dimethoxy-2-nitrobenzyltrichloroacetate and alpha-phenyl

73 ntracellular Ca(2+) by UV uncaging of 1-(4,5-dimethoxy-2-nitrophenyl)-EDTA-potentiated TRPA1 currents

74 oding for luciferase were caged with 1-(4, 5-dimethoxy-2-nitrophenyl)diazoethane (DMNPE) and transfec

75 ld of 0.19 at pH 7; the NAD analog P-[1-(4,5-dimethoxy-2-nitrophenyl)ethyl] NAD (IX) is photolyzed at

76 The affinity caged NADP compound P2'-[1-(4,5-dimethoxy-2-nitrophenyl)ethyl] NADP (VIII) is photolyzed

77 oxy-2-nitrobenzyl-capsaicin and P(3)-[1-(4,5-dimethoxy-2-nitrophenyl)ethyl]-ATP.

78 ficient synthesis of 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene (1c) and hydrochloride (1d

79 f a cellular proliferative marker, N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-(1

80 iodistribution data suggested that N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[1

81 y)-5-methylbenzamide ([18F]3c) and N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[1

82 rides were reacted with isoquinoline and 6,7-dimethoxy-3,4-dihydroisoquinoline to form diastereomeric

83 compared with our founding compound, (S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1

84 e transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydroben

85 tho[2,3-d]furan-6,11-dione (2), 2-chloro-5,8-dimethoxy-3-(3,5-dimethoxyphenoxy)-1,4-naphthoquinone (8

86 ; isoferuloylputrescine; ferulic acid; 22,25-dimethoxy-3-[[2,3,4-tri-O-methyl-6-O-(2,3,4,6-tetra-O-me

87 rally unique tetracyclic enamine, (12bR)-7,9-dimethoxy-3-methyl-1,2,3,7-tetrahydro-7,12b-methanobenzo

88 nd that binds APE1 directly is (E)-3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinonyl)]-2-nonylpropenoic

89 23 steps, respectively, from 5-benzyloxy-2,4-dimethoxy-3-methyl-benzyl alcohol.

90 s, beginning with commercially available 2,4-dimethoxy-3-methylbenzaldehyde (12).

91 scovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (1a) as an inhibitor o

92 identified 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (2a) as a Src inhibito

93 otoberberine analogues containing either 2,3-dimethoxy; 3,4-dimethoxy; or 3, 4-methylenedioxy substit

94 d-twitch response to 5HT(2A)R agonist 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane (DOI).

95 gands flurazepam, flumazenil, and methyl-6,7-dimethoxy-4 ethyl-beta-carboline-3-carboxylate were inac

96 ielded a mass spectrum consistent with 3,3 '-dimethoxy-4,4'-biphenylquinone.

97 rved with mass spectrum consistent with 3,3'-dimethoxy-4,4'-dihydroxybiphenyl.

98 pan-1-ol, (2) benzenemethanol; alpha-[1-[2,6-dimethoxy-4-(2-propen-1-yl)phenoxy]ethyl]-3,4-dimethoxy-

99 4) 1,3-benzodioxate-5-methanol,alpha-[1-[2,6-dimethoxy-4-(2-propenyl)phenoxy]ethyl]- acetate, (5) lic

100 inogenic 5-HT(2A/2C) receptor agonist (-)2,5-dimethoxy-4-bromoamphetamine [(-)DOB].

101 of the hallucinogenic phenethylamine 1 (2,5-dimethoxy-4-bromophenethylamine, 2C-B) was synthesized t

102 opionic acid (Amp) or L- or D-2-amino-3-(6,7-dimethoxy-4-coumaryl)propionic acid (Adp) as the fluorop

103 e inverse benzodiazepine agonist, methyl-6,7-dimethoxy-4-ethyl-beta-carboline (DMCM, 10(-2)M).

104 of IS, because rats treated with methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (1 microg

105 An inverse BZ agonist, methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM; 1

106 with moderate affinity, whereas methyl-6, 7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate inhibited

107 k by the divalent cation zinc and methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, and diff

108 zepine-site ligands, CGS-9895 and methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, had qual

109 s and protected mice against PTZ, methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, picrotox

110 6-containing receptors with the exception of dimethoxy-4-ethyl-beta-carboline-3-carboxylate, which be

111 sensitivity to the beta-carboline methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate.

112 pha-cyano-4-hydroxycinnamic acid (CHCA), 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid, SA), a

113 dehyde and o-phenylenediamine to give 2-(3,5-dimethoxy-4-hydroxyphenyl)benzimidazole coupled with the

114 The effects of [+/-]-2,5-dimethoxy-4-iodoaminophentamine, a serotonin(2A/2C) rece

115 The hallucinogenic chemicals (+/-)-2,5-dimethoxy-4-iodoamphetamine (DOI) and lysergic acid diet

116 the 5-HT2 class of serotonin receptors, 2,5-dimethoxy-4-iodoamphetamine (DOI) and N,N-dimethyllyserg

117 tion of the preferential 5-HT2AR agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) and were more sensitiv

118 WAY-161503 displaced both agonist ([125I]2,5-dimethoxy-4-iodoamphetamine (DOI)) and antagonist ([3H]m

119 behavioral response to the hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI), an agonist for seroto

120 ynthetic 5-HT2AR hallucinogenic agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI), in mice lacking beta-

121 lation in response to the 5-HT2 agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI), suggesting that IL-6

122 anglia with the 5-HT2 receptor agonist R-(+)-dimethoxy-4-iodoamphetamine (R-(+)-DOI, 1 microM) enhanc

123 imicked by the 5-HT(2)-class agonist (-)-2,5-dimethoxy-4-iodoamphetamine and blocked by 5-HT(2) antag

124 ketanserin and were mimicked by 10-20 microM dimethoxy-4-iodoamphetamine but not 10 microM 8-hydroxy-

125 tagonist and spinal application of (+/-)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI) (3.6 and

126 d the 5-HT(2A/2C) receptor agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) resulted

127 with a 5-HT(2A/2C) receptor agonist, (-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI), prevent

128 ute injection of the 5HT2A/C agonist (-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride into the mPFC

129 ct in wild type mice, the 5-HT2R agonist 2,5-dimethoxy-4-iodoamphetamine increased both the baseline

130 5-HT and the 5-HT(2) agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine(.)HCl (DOI) enhanced in vitr

131 Incubation with (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1 microM) abolis

132 inistration of the 5-HT2A/2C agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (2.5 mg/kg,

133 es of rats to the 5-HT(2A/2C) agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and on [(3)

134 The 5-HT(2A/C) agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) desensitize

135 as a marker of maximal ETC activity, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), SRT1720, r

136 this study was to determine if (+/-)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced wet

137 istration of the 5-HT(2A/2C) agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).

138 t and the 5-HT2A/2C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 500, 1500,

139 ased or unchanged affinity for (+/-)-1-)(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin, w

140 The 5-HT(2A/2C) agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI) stimula

141 1A1v), 24-h treatment with 100 nM (-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), a 5-HT

142 the 5-HT2A/2C receptor agonist, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), or DOI

143 e 5-HT(2A/2C) receptor agonist, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), the 5-

144 (+/-)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DO

145 f 5-HT2C receptors with 5-HT or (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane increased release

146 hallucinogenic 5-HT(2A) agonist DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] and decreased mG

147 amide, psilocin, bufotenin, and (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] fell into differ

148 5-HT2A/2C receptor agonist (-)DOI [(-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane].

149 and dopamine (DA), synthetic agonist 1-(2,5-dimethoxy-4-iodophenyl)-aminopropane (DOI), antagonist k

150 and also by the 5-HT2 partial agonist 1-(2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI); the effect

151 eptor subtypes, quipazine and (+/-)-1-[2, 5]-dimethoxy-4-iodophenyl-2-aminopropane), further increase

152 e hallucinogenic 5-HT(2A/2C) agonist 1-[2, 5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) induces exp

153 slices, stimulation of cGMP formation by 2,5-dimethoxy-4-methylamphetamine (DOM), a 5-HT(2A/2C) recep

154 Similarly, the 5-HT(2A/C) agonist [-]-2,5-dimethoxy-4-methylamphetamine (DOM; 0.6 mg/kg, i.p.), wh

155 First, a new, scalable route to 1,1-dimethoxy-4-methylpent-3-en-2-one removes a significant

156 ha,beta-unsaturated ketone-acetal (e.g., 1,1-dimethoxy-4-methylpent-3-en-2-one).

157 identifies the aromatic donor group D = 2,5-dimethoxy-4-methylphenyl to be a suitable redox center f

158 und proved to be methyl 3',3"-dichloro-4',4"-dimethoxy-5', 5"-bis(methoxycarbonyl)-6,6-diphenyl-5-hex

159 proved to be methyl 3',3' '-dibromo-4',4' '-dimethoxy-5',5' '-bis(methoxycarbonyl)-6,6-diphenyl-5-he

160 nt of these proved to be 3',3"-dibromo-4',4"-dimethoxy-5'5"-bis(methoxycarbonyl)-1,1-diphenyl-1-+ ++h

161 of the fluorescent dye 4',5'-dichloro-2',7'-dimethoxy-5(6)-carboxyfluorescein (JOE) is reported; the

162 al reaction of a cyclopentadienone with 6,6'-dimethoxy-5,5'-binaphthoquinone gives, in a single step,

163 when two cyclopentadienones react with 6,6'-dimethoxy-5,5'-binaphthoquinone in nitrobenzene at highe

164 adienones with 5,5'-binaphthoquinone or 6,6'-dimethoxy-5,5'-binaphthoquinone in refluxing nitrobenzen

165 Novel dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarb

166 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenediox

167 amptothecin and comparable to that of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenediox

168 8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenediox

169 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenediox

170 the selective 5-HT(2C)R antagonist 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulfon-amido)phenyl-

171 tive 5-HT(2C) receptor antagonists 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulphonamido) phenyl

172 the oxidation of the ubiquinol analogue, 2,3-dimethoxy-5-methyl-1,4-benzoquinol (UQH2-0), and the pla

173 quinones, including duroquinone (DQ) and 2,3-dimethoxy-5-methyl-1,4-benzoquinone (UQ(0)), the quinone

174 ample of this original series when using 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquino

175 2-(3'-methyl-2',4',6'-trichlorophenoxy)-4,4-dimethoxy-5-methyl-6-chlorocyc lohexadien-2,5-one (7).

176 ganic acetals to give E-configured alkyl 3,5-dimethoxy-5-pent-2-enoates stereoselectively.

177 xy- and 1-[3-(dimethylamino)propyl]amino-7,8-dimethoxy-5H-pyrido[4,3-b]indoles are described.

178 ype ketals 2-(2',4',6'-trichlorophenoxy)-4,4-dimethoxy-6-chlorocyclohexadien-2,5-one (6) and 2-(3'-me

179 toluene generated the dimeric product 3-(2,3-dimethoxy-6-methylphenyl)-4-methyl-1,2-benzoquinone as t

180 ent top1 inhibitors, 6-allyl-5,6-dihydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno[1,

181 d to be cis-6-ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno[1,

182 21) and cis-6-allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno[1,

183 (2-hydroxyethyl)aminopropyl]-5,6-dihydro-2,3-dimethoxy-8, 9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-

184 c) and 5,6-dihydro-6-(4-hydroxybut-1-yl)-2,3-dimethoxy-8, 9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-

185 eno[1,2-c]isoquinoline (26) and 6-ethyl-2, 3-dimethoxy-8,9-(methylenedioxy)-11H-indeno[1,2-c]isoquino

186 hydroxyethyl)amino-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methyle nedioxy-5,11-dioxo-11H-indeno[1,2-

187 Aromatic ring substitution with 2,3-dimethoxy-8,9-methylenedioxy or 3-nitro groups exerted s

188 2,3-Dimethoxy-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoli

189 methylamino)-9H-selenoxanthone (9c), and 2,5-dimethoxy-9H-selenoxanthone (9d) in 70%, 59%, 23%, and 9

190 reen of alphaNF derivatives identifies 3',4'-dimethoxy-alphaNF (DiMNF) as a candidate SAhRM.

191 In contrast to a previous report, the 7,8-dimethoxy analogue of 6 was a low-potency AMPA antagonis

192 The N-methyls of the 2,7-dimethoxy analogue show intrinsic isotope shifts from th

193 ichloro, 3,4,5-trichloro, 3-methoxy, and 2,5-dimethoxy analogues 13-17 were also synthesized.

194 Further evaluation of the 3,5-dimethoxy and 3,4,5-trimethoxy derivatives in chronic ly

195 Efficacy required the dimethoxy and dichlorophenyl groups.

196 Analogues with the 4'-chloro, 3',4'-dimethoxy, and naphthyl side chains (8, 11 and 12) were

197 a-regioisomer, which was demonstrated by 3,5-dimethoxy- and 3,5-bis(trifluoromethyl)-1-phenylethynyls

198 ward the synthesis of mesembrine using a 3,4-dimethoxy aryl group.

199 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (DMXBA

200 viously that the benzylidene group of 3-2,4, dimethoxy-benzylidene anabaseine (GTS-21) converts anaba

201 em) and negative [3-carbomethoxy-4-ethyl-6,7-dimethoxy-beta-carboline (DMCM)] BZD ligands.

202 ), gallic acid (4), caffeic acid (5) and 3,4-dimethoxy cinnamic acid (6).

203 ctive derivatives, compound 1-(4-hydroxy-3,5-dimethoxy) cinnamoyl-2-acyl-sn-glycero-3-phosphocholine

204 lycero-3-phosphocholine and 1-(4-hydroxy-3,5-dimethoxy) cinnamoyl-2-palmitoyl-sn-glycero-3-phosphocho

205 yl]-1,5-gamma-quinide, and 1,3,4-O-tris[3,4-(dimethoxy)cinnamoyl]-1,5-gamma-quinide), finding dissoci

206 ,4-O-dicaffeoyl-1,5-gamma-quinide, 3-O-[3,4-(dimethoxy)cinnamoyl]-1,5-gamma-quinide, 3,4-O-bis[3,4-(d

207 cinnamoyl]-1,5-gamma-quinide, 3,4-O-bis[3,4-(dimethoxy)cinnamoyl]-1,5-gamma-quinide, and 1,3,4-O-tris

208 increased potency relative to the parent 2,5-dimethoxy compounds.

209 In addition, a Michael addition to dimethoxy cyclohexadienones was studied.

210 2',6-Dimethoxy derivative 2 was employed to determine the eff

211 lbene 1,1'-bi(benzocyclobutenylidene) 1, its dimethoxy derivative 5, and from their skeletally rearra

212 sence of an analogous peak from 3,4- and 3,5-dimethoxy derivatives confirmed that this is a diagnosti

213 ciency and chemoselectivity to generate 4,4'-dimethoxy-dicumene 2OMe by decarbonylation and radical c

214 resonance (TREPR) with nanocrystals of 4,4'-dimethoxy-dicumyl ketone (1OMe) suspended in water.

215 oxy (MDO) CPT is much more potent than 10,11-dimethoxy (DMO) CPT; (iv) the lactone portion of CPT is

216 The active 4,6-dimethoxy-ENBPI complexes were more potent than their 3-

217 based on a desymmetrization of alpha,alpha'-dimethoxy-gamma-pyrone by a process combining 1,4-additi

218 wing the hierarchy: 3,4-methylenedioxy > 2,3-dimethoxy >> 3, 4-dimethoxy.

219 This study focused on 2,6-dimethoxy hydroquinone (2,6-DMHQ), an analogue to a comm

220 soflavone (alfalone), and 5,7-dihydroxy-4',6-dimethoxy isoflavone (irisolidone), were induced by YE,

221 -glucopyranoside (4) and 7,5'-dihydroxy-6,3'-dimethoxy-isoflavone-7-O-(7,8-dihydro-p-hydroxycinnamoyl

222 ncluding two isoflavones 7,5'-dihydroxy-6,3'-dimethoxy-isoflavone-7-O-beta-d-glucopyranoside (4) and

223 hyl)aminopropyl]-5,6-dihydro-5,11-diketo-2,3-dimethoxy-(m ethylenedioxy)-11H-indeno[1,2-c]isoquinolin

224 We previously discovered 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phe

225 ine transport through GlyT2 (4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocyclopently)methyl]benzamid

226 Rats were treated in late gestation with 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzene-sulp

227 ture-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoin

228 modified with four photocleavable groups of dimethoxy nitro phenyl ethyl (DMNPE), located on the fou

229 Nitrostilbene and resveratrol, but not dimethoxy-nitrostilbene, engage electrostatic interactio

230 f CYP3A4 than resveratrol, and stronger than dimethoxy-nitrostilbene.

231 ye, VoltageFluor2.1.Cl--or VF--capped with a dimethoxy-o-nitrobenzyl (DMNB) caging group to effective

232 alogues containing either 2,3-dimethoxy; 3,4-dimethoxy; or 3, 4-methylenedioxy substituents all bind

233 A well-characterized inducing factor, 2, 6-dimethoxy-p-benzoquinone (DMBQ), can be used to trigger

234 valence cation radical 3(*)(+) with Ar = 2,5-dimethoxy-p-tolyl (T), in which conformational mobility

235 ular weights (500-6000) and end groups (PEO, dimethoxy-PEO, monomethoxy monomethacrylate-PEO, and dim

236 e used ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-phenethyl)amino] propyloxy)benzenesulfonyl))in

237 The principal products were syringol (2,6-dimethoxy phenol), guaiacol (2-methoxy phenol), phenol,

238 describes a novel molecule, 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-1

239 vidually linked to the PDE4 inhibitor 4-(3,4-dimethoxy-phenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-o

240 ound, O-1966 (1-[4-(1,1-dimethyl-heptyl)-2,6-dimethoxy-phenyl]-3-methyl-cyclohexanol), greatly attenu

241 The dimethoxy ring occupied a deep pocket adjacent to the FA

242 riction of the conformationally flexible 2,5-dimethoxy substituents into fused dihydrofuran rings gen

243 The introduction of 2,7-dimethoxy substituents onto the carbazole moiety lowers

244 opropanation of one of the triple bonds in p-dimethoxy-substituted 3,4-benzocyclodeca-1,5-diyne follo

245 Compound 22, the N9 methyl 2'5'-dimethoxy-substituted analogue was the most potent analo

246 The dimethoxy-substituted benzo[c]phenanthrenes were demethy

247 Molecules with dimethoxy-substituted benzyl groups decomposed more slow

248 ites in a stage-specific manner, the R = 4,6-dimethoxy-substituted ENBPI Fe(III) complex being most p

249 Interestingly, reheating a dimethoxy-substituted giant biaryl (e.g., 21) in nitrobe

250 s of inhibitors was prepared utilizing a 2,3-dimethoxy-substituted isoquinoline ring.

251 In contrast to the 2,5-dimethoxy-substituted phenethylamines, where rigidificat

252 ity studies have concluded that both the 2,5-dimethoxy substitution pattern and the nature of substit

253 evious studies have established that the 2,5-dimethoxy substitution pattern found in these compounds

254 ed structure-affinity relationships, the 2,5-dimethoxy substitution pattern is no longer a requiremen

255 Thus, not only is the 2,5-dimethoxy substitution pattern not a requirement for the

256 That is, the 2,5-dimethoxy substitution pattern of 3 is not required for

257 ating the substituted nitroanilines with 2,5-dimethoxy-tetrahydrofuran to afford the nitropyrrole int

258 ing alternative substituents in place of the dimethoxy unit.

259 ounds 4ka (X = 3-isobutoxy) and 4kc (X = 3,5-dimethoxy) with k = 2, 3, 4, and 5) was obtained from th